-
Express | 74% of patients have sustained remission for more than 18 months, and Gilead's CAR-T therapy gains the third indication
Time of Update: 2021-03-23
▎Kite Pharma, an editor of WuXi AppTec's content team, recently announced that the US FDA has accelerated the approval of the CAR-T therapy Yescarta (axicabtagene ciloleucel) as an extended indication for the treatment of relapsed/refractory follicular lymphoma (FL) Adult patients.
-
CAR-T cell therapy Idecabtagene Vicleucel in the treatment of relapsed and refractory multiple myeloma: results of phase II KarMMa study
Time of Update: 2021-03-23
A median of 128 patients who received ide-cel infusion received 6 treatments for myeloma (range: 3-16 times), of which 120 (94%) patients had previously received autologous hematopoietic stem cell transplantation.
-
Isartuximab combined with dexamethasone significantly improves the efficacy of patients with relapsed and refractory multiple myeloma
Time of Update: 2021-03-23
The study further compared the efficacy and safety of ixatuximab single-agent regimen and ixatuximab combined with dexamethasone regimen in RRMM patients.
2% of the patients in the combined regimen group had grade ≥3 TEAEs that may be related to the therapeutic drugs (as shown in the figure below).
-
Science | Song Yuanbin/Shan Liang et al. Develop a new humanized mouse model of human red blood cell growth and maturation
Time of Update: 2021-03-23
In recent years, Stephanie Halene, as the corresponding author, has published many research papers in internationally renowned journals such as Science, Immunity, Blood, and Nature Communications.
-
NEJM review: diffuse large B-cell lymphoma (pictured: new drugs, treatment processes, prognosis, molecular division)
Time of Update: 2021-03-23
In the past 20 years, we have gained in-depth understanding of the epidemiology, prognostic factors, and biological heterogeneity of large B-cell lymphoma, improved the classification of diseases, and developed new therapies.
-
2021 EBMT | Chinese Experts International speak again, wonderful inventory, not to be missed!
Time of Update: 2021-03-23
Come to the message area and tell us~~~Poke "read the original text" and we will make progress together Speaker: Jingli Gu Unit: From today, the First Affiliated Hospital of Sun Yat-Sen University, the Department of Hematology of Yimaitong will carry out a series of reports on the 2021 EBMT conference.
-
A major breakthrough in leukemia treatment has made it possible to increase the survival rate by 30%!
Time of Update: 2021-03-23
Chi Wai Eric So, Professor of Leukemia Biology and Chairman, King’s College London, published a study in Science Translational Medicine through the use of highly purified human hematopoietic stem cells for prospective disease modeling and primary patients A review of the leukemia stem cells (LSCs) in the sample revealed that human hematopoietic stem cells (HSCs) and common bone marrow progenitor cells (CMPs) are two types of human acute myeloid leukemia (MLL-AML) driven by the fusion of mixed-lineage leukemia (MLL) genes.
-
CAR-T cell side effects of infection | CAR-T cell treatment of NHL side effects clinical management expert consensus
Time of Update: 2021-03-23
. The Biotherapeutics Committee of the Chinese Research Hospital Association organized experts to compile the "Expert Consensus on the Clinical Management of CAR-T Cells Treating NHL Toxic Side Effects", which aims to provide clinicians with a more standardized identification and treatment of CAR-T treatment of NHL-related side effects The disposal principles and exploratory disposal recommendations.
-
Science | Hope to solve the bottleneck in the field!
Time of Update: 2021-03-23
The study reports a mouse model of immunodeficiency in which a combination of human liver and cytokine humanization confers enhanced human erythropoiesis and RBC survival in the circulation.
-
Professor Wang Jianxiang: More flowers, talk about the application of geritinib in FLT3 mutation-positive AML
Time of Update: 2021-03-23
In addition, there is also a phase 3 open randomized trial showing that the combination of geritinib and azacitidine in the treatment of FLT3 mutant AML that is not suitable for intensive induction chemotherapy, the CRc rate of the safety cohort was 67%4.
-
Express | Reducing the risk of disease recurrence by 67%, Amgen's bispecific antibody therapy phase 3 clinical results released
Time of Update: 2021-03-23
▎Amgen, the editor of WuXi AppTec's content team, today announced a phase 3 clinical trial of bispecific antibody therapy Blincyto (blinatumomab) for the first relapse of high-risk B-cell precursor acute lymphoblastic leukemia (B-ALL) in children The results were published in the Journal of the American Medical Association (JAMA).
-
2021 EBMT | China Research Report
Time of Update: 2021-03-22
Liu Unit: Peking University Blood The conclusion of the brief study by the Institute of Disease Research: Granulocyte colony stimulating factor (G-CSF) can up-regulate the expression of PD-1 in donor’s peripheral blood CD8+ CD45RA+ CCR7+ T cells, which may help to reduce allogeneic hematopoietic stem cell transplantation (alloHCT) The severity of acute graft-versus-host disease (aGVHD).
-
Decitabine + Carrelizumab is safe and effective in the treatment of R/R cHL: the latest research results of Professor Han Weidong’s team
Time of Update: 2021-03-22
In the test cohort, all 20 patients with CR, PR or SD who were treated with decitabine + carrelizumab had longer PFS than previous PD-1 inhibitor monotherapy (Figure 2C).
-
The gene therapy for hemophilia A, which was rejected by the FDA, is now designated as an advanced therapy for regenerative medicine.
Time of Update: 2021-03-22
Don’t get hair transplants, let’s take a look at the magic of stem cell therapyMedClub New Observation March 10, 2021/MedClub News/--March 8, 2021, BioMarin announced that the US Food and Drug Administration (FDA) awarded the company valoctocogene roxaparvovec (hereinafter referred to as: valrox) Regenerative Medicine Advanced Therapy Designation (RMAT), a gene therapy candidate product for hemophilia A.
-
Clin Cancer Res: Decitabine combined with anti-PD-1 antibody can effectively improve the prognosis of patients with progressive/recurrent Hodgkin’s lymphoma
Time of Update: 2021-03-22
In total, a total of 51 patients (test cohort: 25, extended cohort: 26) received decitabine combined with anti-PD-1 therapy, of which 50 patients were included in the efficacy evaluation.
The median progression-free survival of patients treated with decitabine combined with camrelizumab in the test cohort and the extended cohort was 20.
-
Clinical Practice Guidelines Update: SITC Lymphoma Immunotherapy Guidelines
Time of Update: 2021-03-22
However, in the randomized phase III ECHELON-1 trial (NCT01712490), a median follow-up of 1334 patients with stage III/IV cHL who had not received treatment in the past 2 years showed that patients in the A-AVD regimen treatment group had progression-free survival ( PFS) rate is significantly higher.
-
2021 EBMT | Bendamustine pretreatment regimen improves the prognosis of transplanted R/R NHL patients
Time of Update: 2021-03-22
01 Research method The study reviewed 131 patients who received Benda-EAM pretreatment between May 2015 and May 2018, and 96 patients who received carmustine pretreatment between January 2012 and May 2015 The patients of the protocol were analyzed, and the baseline characteristics, adverse reactions and post-transplant results of the two groups of patients were compared.
-
FDA Update | Accelerated approval of axicabtagene ciloleucel for the treatment of patients with relapsed and refractory follicular lymphoma
Time of Update: 2021-03-22
S. Food and Drug Administration (FDA) accelerated the approval of axicabtagene ciloleucel for adult patients with relapsed and refractory follicular lymphoma (FL) who had previously received ≥2 lines of systemic therapy.
-
2021 EBMT | Venecla combined with hypomethylation drugs is safe and effective in the treatment of high-risk AML, which can effectively bridge transplantation
Time of Update: 2021-03-22
At a median follow-up of 5 months (range: 1-22), 14 of the 24 patients (58%) were alive, of which 5 (21%) patients were still receiving treatment or were in complete remission.
-
2021 EBMT | Rucotinib GVHD treatment journey, REACH3 research update
Time of Update: 2021-03-21
The results of a multicenter randomized controlled phase III REACH2 study showed that in patients with grade II-IV SR-aGvHD ≥12 years old, the efficacy of rucotinib is better than the best available treatment (BAT), which can significantly improve the overall remission of patients Rate (ORR, ORR on day 28 was 62.
